These findings with a JAK2 selective inhibitor, fedratinib, together with the previously reported effects of the JAK1/JAK2 inhibitor ruxolitinib, indicate that improvement or even resolution of BMF in some patients with myelofibrosis may be achievable with JAK2 inhibitor therapy. Here, JAK1 is linked to myelofibrosis.